Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes
Filana Therapeutics Announces Fifth Circuit Rules Texas District Court Misapplied Legal Standard In Class Certification
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Filana Therapeutics shares are trading higher after the company announced that the FDA lifted the clinical hold on its investigational new drug application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Filana Therapeutics Announces Publication In Epilepsia Of Preclinical Data Showing Simufilam Attenuated Seizure Progression In Mouse Model Of Severe TSC-Related Epilepsy
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.